Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Workday
WDAY
|
+$574M |
| 2 |
TotalEnergies
TTE
|
+$573M |
| 3 |
MDLN
Medline Inc
MDLN
|
+$446M |
| 4 |
Micron Technology
MU
|
+$389M |
| 5 |
Canadian Pacific Kansas City
CP
|
+$387M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$1.19B |
| 2 |
Microsoft
MSFT
|
+$1.11B |
| 3 |
Mastercard
MA
|
+$557M |
| 4 |
Autodesk
ADSK
|
+$554M |
| 5 |
RNAM
Avidity Biosciences
RNAM
|
+$490M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34.83% |
| 2 | Healthcare | 19.29% |
| 3 | Consumer Discretionary | 9.89% |
| 4 | Financials | 9.74% |
| 5 | Industrials | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Ligand Pharmaceuticals
LGND
$5.96B
| $188M | 0.08% |
995,400
-46,978
| -5% | -$9.03M |
|
202
RTX Corp
RTX
$294B
| $187M | 0.08% |
1,019,504
-35,795
| -3% | -$6.22M |
|
203
Ares Management
ARES
$28.8B
| $186M | 0.08% |
1,149,390
+153,488
| +15% | +$23.9M |
|
204
Xenon Pharmaceuticals
XENE
$6.36B
| $183M | 0.08% |
4,084,034
+140,149
| +4% | +$5.89M |
|
205
AXIS Capital
AXS
$8.63B
| $181M | 0.08% |
1,689,901
-81,299
| -5% | -$8.08M |
|
206
Keysight
KEYS
$53.6B
| $180M | 0.08% |
883,643
+168,698
| +24% | +$31.3M |
|
207
Tyler Technologies
TYL
$13B
| $177M | 0.08% |
390,957
-21,602
| -5% | -$10.3M |
|
208
Zurn Elkay Water Solutions
ZWS
$8.14B
| $177M | 0.08% |
3,810,427
-271,916
| -7% | -$12.8M |
|
209
Sterling Infrastructure
STRL
$19.5B
| $176M | 0.08% |
575,886
+20,299
| +4% | +$6.99M |
|
210
CarMax
KMX
$8.29B
| $175M | 0.08% |
4,530,820
-344,409
| -7% | -$13.8M |
|
211
OneMain Financial
OMF
$7.08B
| $171M | 0.08% |
2,534,271
+1,047,263
| +70% | +$63.7M |
|
212
Teck Resources
TECK
$29.3B
| $171M | 0.08% |
3,564,732
-3,702,261
| -51% | -$160M |
|
213
Verizon
VZ
$198B
| $170M | 0.08% |
4,171,670
-119,734
| -3% | -$4.86M |
|
214
Olema Pharmaceuticals
OLMA
$1.05B
| $168M | 0.08% |
6,710,194
+3,124,345
| +87% | +$55.6M |
|
215
Apollo Global Management
APO
$71.6B
| $163M | 0.07% |
1,128,920
+5,528
| +0.5% | +$734K |
|
216
Cogent Biosciences
COGT
$6.91B
| $161M | 0.07% |
4,537,408
+1,359,365
| +43% | +$38.2M |
|
217
Wingstop
WING
$3.74B
| $161M | 0.07% |
675,301
+31,618
| +5% | +$7.83M |
|
218
Prologis
PLD
$137B
| $161M | 0.07% |
1,259,369
-480,277
| -28% | -$59.9M |
|
219
Regeneron Pharmaceuticals
REGN
$69.9B
| $159M | 0.07% |
205,672
+131,929
| +179% | +$89.6M |
|
220
Tarsus Pharmaceuticals
TARS
$2.62B
| $158M | 0.07% |
1,930,325
+491,326
| +34% | +$36.7M |
|
221
Apogee Therapeutics
APGE
$10.2B
| $156M | 0.07% |
2,062,604
+1,576,626
| +324% | +$99.3M |
|
|
NUVL
222
DELISTED
Nuvalent
NUVL
| $151M | 0.07% |
1,499,574
-689,100
| -31% | -$67.9M |
|
223
Emerson Electric
EMR
$83.6B
| $150M | 0.07% |
1,128,042
+679,706
| +152% | +$90.2M |
|
224
Teva Pharmaceuticals
TEVA
$36.2B
| $148M | 0.07% |
4,743,777
-59,696
| -1% | -$1.47M |
|
225
Penumbra
PEN
$12.6B
| $148M | 0.07% |
475,898
+7,050
| +2% | +$1.95M |
|
Similar funds
Janus Henderson Group's Q4 2025 Portfolio in Review
As of Q4 2025, Janus Henderson Group held 2,496 positions worth $223B, up 1.9% from $219B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Janus Henderson Group's Q4 2025 filing shows 100 new, 812 increased, 609 reduced and 90 closed positions. Its largest new stake was TotalEnergies: 9,061,622 shares worth $591M. The largest sale was Meta Platforms (Facebook), an estimated $1.19B.
By sector, the portfolio is most concentrated in Technology at 35% of assets, down from 37% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Janus Henderson Group's largest Q4 2025 buy was TotalEnergies: 9,061,622 shares worth $591M.
- Janus Henderson Group added most to Workday in Q4 2025, an estimated $574M increase.
- Janus Henderson Group's biggest Q4 2025 reduction was Meta Platforms (Facebook), cutting an estimated $1.19B.
- Janus Henderson Group fully exited Akero Therapeutics in Q4 2025, selling an estimated $298M.
- Janus Henderson Group's ten largest holdings make up 33% of its $223B portfolio in Q4 2025.
- Janus Henderson Group opened 100 new positions and closed 90 in Q4 2025.
- Janus Henderson Group's portfolio value rose 1.9% quarter-over-quarter to $223B.
Based on Janus Henderson Group's 13F filing for Q4 2025, filed 17 Feb 2026.